🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for High-risk Non-muscle Invasive Bladder Cancer

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection NCT06525571Phase 32 sites📍 Washington D.C.📍 Baltimore Johns Hopkins University · Tests: Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488Phase 1, Phase 217 sites📍 Bakersfield📍 New Brunswick📍 Myrtle Beach Merck Sharp & Dohme LLC · Tests: MK-3120 Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer NCT07475403Phase 23 sites📍 Tianjin📍 Tianjin📍 Xingtai Tianjin Medical University Second Hospital · Tests: Systemic immunotherapy LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve NCT04752722Phase 1, Phase 2102 sites📍 Birmingham📍 Scottsdale📍 Tucson enGene, Inc. · Tests: EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy NCT07000084Phase 360 sites📍 Birmingham📍 Fairbanks📍 Gilbert Alliance for Clinical Trials in Oncology · Tests: BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) NCT06108492Phase 11 site📍 Shanghai Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-2005 Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) NCT05825950n/a2 sites📍 Dallas📍 San Antonio University of Texas Southwestern Medical Center Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) NCT07763197n/a1 site📍 Austin Natera, Inc. Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? NCT07625527Phase 24 sites📍 Tianjin📍 Tianjin📍 Tianjin Tianjin Medical University Second Hospital · Tests: Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263Phase 21 site📍 Iowa City Michael A. O'Donnell · Tests: Intravesical Gemcitabine and Docetaxel A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer NCT06919965Phase 3114 sites📍 Sun City📍 Los Angeles📍 Lakewood Janssen Research & Development, LLC · Tests: TAR-210, Mitomycin C, Gemcitabine Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients NCT06696794Phase 33 sites📍 Wuhan📍 Wuhan📍 Xiangyang Shaogang Wang · Tests: Mitomycin C (MMC), Normal Saline (Placebo) Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer NCT07480356Phase 311 sites📍 Queen Creek📍 Little Rock📍 Bakersfield Protara Therapeutics · Tests: TARA-002, Investigator's Choice of Intravesical Chemotherapy Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration NCT07307456Phase 21 site📍 Shanghai Changhai Hospital · Tests: Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT) Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) NCT05037279Phase 36 sites📍 Vancouver📍 Kingston📍 Toronto Verity Pharmaceuticals Inc. · Tests: Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 NCT06378242Phase 1, Phase 26 sites📍 Guangzhou📍 Wuhan📍 Changsha RemeGen Co., Ltd. · Tests: Disitamab Vedotin for injection A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing NCT07036731NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC NCT05410730Phase 1, Phase 21 site📍 Beijing Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-1501 Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer NCT06441110Phase 31 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: Tislelizumab in Combination with Bacillus Calmette-Guérin Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin NCT07283835Phase 214 sites📍 Beijing📍 Chongqing📍 Fuzhou Lepu Biopharma Co., Ltd. · Tests: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer NCT05710848Phase 1, Phase 220 sites📍 Mesa📍 Tucson📍 Little Rock SURGE Therapeutics · Tests: STM-416 A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy NCT07468851Phase 1, Phase 22 sites📍 Beijing📍 Nanjing Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: HS-10566, HS-10566, HS-10566 Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC NCT06567743Phase 280 sites📍 Gilbert📍 Phoenix📍 Tucson CG Oncology, Inc. · Tests: Cretostimogene Grenadenorepvec A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC NCT06971614Phase 29 sites📍 Queen Creek📍 Los Angeles📍 Orlando ImmVira Pharma Co. Ltd · Tests: T3011 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal NCT07784387n/a1 site📍 Lisbon Janssen-Cilag Farmaceutica Ltda. A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC NCT07726992Phase 32 sites📍 Beijing📍 Guangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-1501+BCG, Placebo +BCG RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects NCT05943379Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: RC48-ADC in Combination with gemcitabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy